Kaleido Stock Analysis

KLDO -  USA Stock  

USD 0.05  0.009  14.29%

The big decline in price over the last few months for Kaleido Biosciencesmay raise some interest from institutional investors. The stock closed today at a share price of 0.054 on very low momentum in trading volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in April. However, diversifying your holdings with Kaleido Biosciences or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 19.88. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Kaleido Biosciences partners.
Please see Stocks Correlation.
  
Refresh
The Kaleido Biosciences stock analysis report makes it easy to digest most publicly released information about Kaleido Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Kaleido Stock analysis module also helps to analyze the Kaleido Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Kaleido Stock Analysis Notes

About 65.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.08. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kaleido Biosciences recorded a loss per share of 2.24. The entity had not issued any dividends in recent years. Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. To find out more about Kaleido Biosciences contact Mike Bonney at 617 674 9000 or learn more at https://kaleido.com.

Kaleido Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kaleido Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kaleido Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kaleido Biosciences generated a negative expected return over the last 90 days
Kaleido Biosciences has high historical volatility and very poor performance
Kaleido Biosciences has some characteristics of a very speculative penny stock
Kaleido Biosciences has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 1.1 M. Net Loss for the year was (90.29 M) with loss before overhead, payroll, taxes, and interest of (66.7 M).
Kaleido Biosciences currently holds about 38.47 M in cash with (77.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Kaleido Biosciences has a frail financial position based on the latest SEC disclosures
Roughly 65.0% of the company shares are owned by institutional investors
Latest headline from www.fiercebiotech.com: AviadoBio gains orphan tag for one-dose dementia gene therapy - FierceBiotech

Kaleido Biosciences Upcoming and Recent Events

Earnings reports are used by Kaleido Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kaleido Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report2nd of March 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End2nd of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Kaleido Biosciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kaleido Biosciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kaleido Biosciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kaleido Biosciences specific information freely available to individual and institutional investors to make a timely investment decision.
10th of May 2022
Unclassified Corporate Event
View
8th of April 2022
Financial Statements and Exhibits. Other Events. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
31st of March 2022
Other Events
View
17th of March 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
9th of March 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
9th of February 2022
Unclassified Corporate Event
View
28th of January 2022
Other Events
View
1st of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Kaleido Market Capitalization

The company currently falls under 'Nano-Cap' category with current market capitalization of 2.28 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kaleido Biosciences's market, we take the total number of its shares issued and multiply it by Kaleido Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Kaleido Profitablity

Kaleido Biosciences' profitability indicators refer to fundamental financial ratios that showcase Kaleido Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Kaleido Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Kaleido Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Kaleido Biosciences' profitability requires more research than a typical breakdown of Kaleido Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(1.18) (1.27) 
Return on Average Equity(2.23) (2.29) 
Return on Invested Capital(6.75) (7.29) 
Return on Sales(79.21) (85.46) 

Management Efficiency

The entity has return on total asset (ROA) of (99.93) % which means that it has lost $99.93 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (580.57) %, meaning that it created substantial loss on money invested by shareholders. Kaleido Biosciences management efficiency ratios could be used to measure how well kaleido biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -1.27. The value of Return on Average Equity is estimated to slide to -2.29. Kaleido Biosciences Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 62.03 Million
Last ReportedProjected for 2022
Book Value per Share 0.25  0.28 
Enterprise Value over EBIT(1.00) (1.08) 
Enterprise Value over EBITDA(0.77) (0.83) 
Price to Book Value 9.60  10.58 
Tangible Assets Book Value per Share 1.20  1.23 
Enterprise Value65.5 M96.1 M
Tangible Asset Value50.1 M62 M

Technical Drivers

As of the 23rd of May, Kaleido Biosciences secures the mean deviation of 10.22, and Risk Adjusted Performance of (0.16). Kaleido Biosciences technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down nineteen technical drivers for Kaleido Biosciences, which can be compared to its peers in the industry. Please verify Kaleido Biosciences coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Kaleido Biosciences is priced some-what accurately, providing market reflects its recent price of 0.054 per share. As Kaleido Biosciences appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.

Kaleido Biosciences Price Movement Analysis

The output start index for this execution was six with a total number of output elements of fifty-five. Kaleido Biosciences Triple Exponential Moving Average indicator shows smoothing effect of Kaleido Biosciences price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Kaleido Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kaleido Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kaleido Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kaleido Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Van Hylckama Vlieg Johan over two months ago via Macroaxis 
Payment of 2087 shares by Van Hylckama Vlieg Johan of Kaleido Biosciences subject to Rule 16b-3
Long Alison S over three months ago via Macroaxis 
Acquisition by Long Alison S of 125000 shares of Kaleido Biosciences subject to Rule 16b-3
Long Alison S over three months ago via Macroaxis 
Acquisition by Long Alison S of 24350 shares of Kaleido Biosciences subject to Rule 16b-3
Flagship Ventures Fund V General Partner Llc over three months ago via Macroaxis 
Conversion by Flagship Ventures Fund V General Partner Llc of 426240 shares of Kaleido Biosciences
Van Hylckama Vlieg Johan over six months ago via Macroaxis 
Acquisition by Van Hylckama Vlieg Johan of 40000 shares of Kaleido Biosciences subject to Rule 16b-3
Prener Anne over six months ago via Macroaxis 
Acquisition by Prener Anne of 15000 shares of Kaleido Biosciences subject to Rule 16b-3
Van Hylckama Vlieg Johan over a year ago via Macroaxis 
Kaleido Biosciences exotic insider transaction detected
Jerald Korn over a year ago via Macroaxis 
Acquisition by Jerald Korn of 60000 shares of Kaleido Biosciences subject to Rule 16b-3
Menichella Daniel L over a year ago via Macroaxis 
Purchase by Menichella Daniel L of 20000 shares of Kaleido Biosciences
Flagship Ventures Fund Iv General Partner Llc over a year ago via Macroaxis 
Kaleido Biosciences exotic insider transaction detected
Jerald Korn over a year ago via Macroaxis 
Acquisition by Jerald Korn of 45000 shares of Kaleido Biosciences subject to Rule 16b-3
Prener Anne over a year ago via Macroaxis 
Acquisition by Prener Anne of 15000 shares of Kaleido Biosciences subject to Rule 16b-3

Kaleido Biosciences Technical and Predictive Indicators

Kaleido Biosciences Forecast Models

Kaleido Biosciences time-series forecasting models is one of many Kaleido Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kaleido Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Kaleido Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kaleido Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kaleido shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Kaleido Biosciences. By using and applying Kaleido Stock analysis, traders can create a robust methodology for identifying Kaleido entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(77.08) (83.16) 
Gross Margin 0.90  0.89 
Profit Margin(81.78) (88.24) 
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people.

Current Kaleido Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kaleido analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kaleido analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
13.75Hold4Odds
Kaleido Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Kaleido analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kaleido stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kaleido Biosciences, talking to its executives and customers, or listening to Kaleido conference calls.
Kaleido Analyst Advice Details

Kaleido Stock Analysis Indicators

Kaleido Biosciences stock analysis indicators help investors evaluate how Kaleido Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kaleido Biosciences shares will generate the highest return on investment. By understating and applying Kaleido Biosciences stock analysis, traders can identify Kaleido Biosciences position entry and exit signals to maximize returns.
Quick Ratio1.33
Fifty Two Week Low0.0410
Revenue Growth102.50%
Shares Short Prior Month2.16M
Average Daily Volume Last 10 Day435.28k
Average Daily Volume In Three Month5.28M
Shares Percent Shares Out5.49%
Short Percent Of Float14.19%
Forward Price Earnings-0.06
Float Shares22.87M
Fifty Two Week High9.4700
Enterprise Value To Ebitda0.17
Fifty Day Average0.7277
Two Hundred Day Average3.0897
Enterprise Value To Revenue-13.27
Please see Stocks Correlation. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Kaleido Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kaleido Biosciences. If investors know Kaleido will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kaleido Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.